Bristol-Myers Squibb Company (BMY) and ZymoGenetics, Inc. (ZGEN) Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
11/2/2009 9:27:01 AM
More...
|
Mixed Data for AstraZeneca PLC (AZN) (JOBS) and Bristol-Myers Squibb Company (BMY) (JOBS) Diabetes Drug in New Phase III Study
10/21/2009 8:44:53 AM
More...
|
Bristol-Myers Squibb Company (BMY): ORENCIA(R) (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration)
10/19/2009 8:53:29 AM
More...
|
Bristol-Myers Squibb Company (BMY): Study Finds That ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus
10/5/2009 10:09:15 AM
More...
|
Bristol-Myers Squibb Company (BMY): ONGLYZATM (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes
10/5/2009 10:07:47 AM
More...
|
Bristol-Myers Squibb Company (BMY) to Announce Results for the Third Quarter of 2009 on October 22
10/2/2009 8:43:00 AM
More...
|
New Data on Four Bristol-Myers Squibb Company (BMY) Compounds to Be Presented at AASLD 2009
10/1/2009 11:28:15 AM
More...
|
Bristol-Myers Squibb Company (BMY) and ZymoGenetics, Inc. (ZGEN) to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009
10/1/2009 11:06:13 AM
More...
|
Bristol-Myers Squibb Company (BMY): Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
9/23/2009 9:24:10 AM
More...
|
Bristol-Myers Squibb Company (BMY) (JOBS) Sells Asia Rights to Japan's Taisho Pharmaceutical for $310 Million
9/16/2009 7:02:01 AM
More...
|
|